Literature DB >> 29711002

Metals in Medicine.

Zijian Guo1, Peter J Sadler1.   

Abstract

Not only the 24 or so essential elements, but also nonessential and even radioactive elements have enormous potential for applications in medicine. In the fight against cancer cisplatin, one of the world's best selling anticancer drugs, is being joined by other platinum, titanium, and ruthenium complexes. Gadolinium(III) complexes can be safely injected as magnetic resonance imaging contrast agents, and ligand design allows targeting of paramagnetic ions as well as radiodiagnostic (e.g. 99m Tc) and radiotherapeutic isotopes (e.g. 186 Re). Manganese superoxide dismutase mimics, vanadium insulin mimics, ruthenium nitric oxide scavengers, lanthanide-based photosensitizers, and metal-targeted organic agents show exciting clinical potential. © 1999 WILEY-VCH Verlag GmbH, Weinheim, Fed. Rep. of Germany.

Entities:  

Keywords:  Bioinorganic chemistry; Coordination chemistry; Drug research; Medicinal chemistry; Metallodrugs

Year:  1999        PMID: 29711002     DOI: 10.1002/(SICI)1521-3773(19990601)38:11<1512::AID-ANIE1512>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  20 in total

1.  Hexanuclear self-assembled arene-ruthenium nano-prismatic cages: potential anticancer agents.

Authors:  Vaishali Vajpayee; Yoon Jung Yang; Se Chan Kang; Hyunuk Kim; In Su Kim; Ming Wang; Peter J Stang; Ki-Whan Chi
Journal:  Chem Commun (Camb)       Date:  2011-03-30       Impact factor: 6.222

2.  Comparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN'O] ligands as 26S proteasome inhibitors.

Authors:  Michael Frezza; Sarmad Sahiel Hindo; Dajena Tomco; Marco M Allard; Qiuzhi Cindy Cui; Mary Jane Heeg; Di Chen; Q Ping Dou; Cláudio N Verani
Journal:  Inorg Chem       Date:  2009-07-06       Impact factor: 5.165

3.  Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design.

Authors:  Pieter C A Bruijnincx; Peter J Sadler
Journal:  Adv Inorg Chem       Date:  2009-07-07       Impact factor: 3.282

Review 4.  Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside.

Authors:  Stephen Ahenkorah; Irwin Cassells; Christophe M Deroose; Thomas Cardinaels; Andrew R Burgoyne; Guy Bormans; Maarten Ooms; Frederik Cleeren
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

5.  Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation.

Authors:  Euan Ramsay; Jehan Alnajim; Malathi Anantha; Aman Taggar; Anitha Thomas; Katarina Edwards; Göran Karlsson; Murray Webb; Marcel Bally
Journal:  Pharm Res       Date:  2006-10-25       Impact factor: 4.580

6.  In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.

Authors:  R E Aird; J Cummings; A A Ritchie; M Muir; R E Morris; H Chen; P J Sadler; D I Jodrell
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

7.  Synthesis, characterization and biological evaluation of Pd(ii), Cu(ii), Re(i) and 99mTc(i) thiazole-based complexes.

Authors:  Jelena M Mašković; Antonios Hatzidimitriou; Ana Damjanović; Tatjana P Stanojković; Srećko R Trifunović; Athina A Geronikaki; Dionysia Papagiannopoulou
Journal:  Medchemcomm       Date:  2018-04-13       Impact factor: 3.597

Review 8.  New trends for metal complexes with anticancer activity.

Authors:  Pieter C A Bruijnincx; Peter J Sadler
Journal:  Curr Opin Chem Biol       Date:  2008-01-25       Impact factor: 8.822

9.  Synthesis, Characterization, and Antibacterial Studies of Pd(II) and Pt(II) Complexes of Some Diaminopyrimidine Derivatives.

Authors:  Peter A Ajibade; Omoruyi G Idemudia
Journal:  Bioinorg Chem Appl       Date:  2013-03-12       Impact factor: 7.778

10.  Metal ion as both a cofactor and a probe of metal-binding sites in a uranyl-specific DNAzyme: a uranyl photocleavage study.

Authors:  Marjorie Cepeda-Plaza; Eric L Null; Yi Lu
Journal:  Nucleic Acids Res       Date:  2013-08-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.